UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2019
OR
TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______ to _______
COMMISSION FILE NUMBER 1-3619
----
PFIZER INC.
(Exact name of registrant as specified in its charter)
DELAWARE
(State of Incorporation)
13-5315170
(I.R.S. Employer Identification No.)
235 East 42nd Street, New York, New York 10017
(Address of principal executive offices) (zip code)
(212) 733-2323
(Registrant s telephone number)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
YES X
NO ___
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
YES X
NO ___
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act:
Large Accelerated filer X Accelerated filer ___ Non-accelerated filer ___ Smaller reporting company ___ Emerging growth company ___
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ___
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
YES ____
NO X
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $.05 par value
PFE
New York Stock Exchange
0.000% Notes due 2020
PFE20A
New York Stock Exchange
0.250% Notes due 2022
PFE22
New York Stock Exchange
1.000% Notes due 2027
PFE27
New York Stock Exchange
At May 6, 2019, 5,559,929,190 shares of the issuer s voting common stock were outstanding.
Table of Contents
PART I. FINANCIAL INFORMATION
Page
Item 1.
Financial Statements
Condensed Consolidated Statements of Income for the three months ended March 31, 2019 and April 1, 2018
Condensed Consolidated Statements of Comprehensive Income for the three months ended March 31, 2019 and April 1, 2018
Condensed Consolidated Balance Sheets as of March 31, 2019 and December 31, 2018
Condensed Consolidated Statements of Equity for the three months ended March 31, 2019 and April 1, 2018
Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2019 and April 1, 2018
Notes to Condensed Consolidated Financial Statements
10
Review Report of Independent Registered Public Accounting Firm
43
Item 2.
Management s Discussion and Analysis of Financial Condition and Results of Operations
44
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
93
Item 4.
Controls and Procedures
93
PART II. OTHER INFORMATION
Item 1.
Legal Proceedings
94
Item 1A.
Risk Factors
94
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
95
Item 3.
Defaults Upon Senior Securities
95
Item 4.
Mine Safety Disclosures
95
Item 5.
Other Information
95
Item 6.
Exhibits
96
Signature
97
GLOSSARY OF DEFINED TERMS
Unless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Quarterly Report on Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. We also have used several other terms in this Quarterly Report on Form 10-Q, most of which are explained or defined below:
2018 Financial Report
Financial Report for the fiscal year ended December 31, 2018, which was filed as Exhibit 13 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2018
2018 Form 10-K
Annual Report on Form 10-K for the fiscal year ended December 31, 2018
ACA (Also referred to as U.S. Healthcare Legislation)
U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act
ACIP
Advisory Committee on Immunization Practices
ALK
anaplastic lymphoma kinase
Alliance revenues
Revenues from alliance agreements under which we co-promote products discovered or developed by other companies or us
Allogene
Allogene Therapeutics, Inc.
Anacor
Anacor Pharmaceuticals, Inc.
AOCI
Accumulated Other Comprehensive Income
Astellas
Astellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc.
Bamboo
Bamboo Therapeutics, Inc.
Biopharma
Pfizer Biopharmaceuticals Group
BMS
Bristol-Myers Squibb Company
BRCA
BReast CAncer susceptibility gene
CAR T
chimeric antigen receptor T cell
CDC
U.S. Centers for Disease Control and Prevention
cGMP
current Good Manufacturing Practices
Citibank
Citibank, N.A.
Developed Markets
U.S., Western Europe, Japan, Canada, South Korea, Australia, Scandinavian countries, Finland and
New Zealand
EEA
European Economic Area
EGFR
epidermal growth factor receptor
EH
Essential Health
EMA
European Medicines Agency
Emerging Markets
Includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea),
Latin America, Eastern Europe, the Middle East, Africa, Central Europe and Turkey
EPS
earnings per share
EU
European Union
Exchange Act
Securities Exchange Act of 1934, as amended
FASB
Financial Accounting Standards Board
FDA
U.S. Food and Drug Administration
GAAP
Generally Accepted Accounting Principles
GIST
gastrointestinal stromal tumors
GPD
Global Product Development organization
GSK
GlaxoSmithKline plc
GS&Co.
Goldman, Sachs & Co. LLC
HER2-
human epidermal growth factor receptor 2-negative
hGH-CTP
human growth hormone
HIS
Hospira Infusion Systems
Hisun Pfizer
Hisun Pfizer Pharmaceuticals Company Limited
Hospira
Hospira, Inc.
HR+
hormone receptor-positive
ICU Medical
ICU Medical, Inc.
IH
Innovative Health
IPR&D
in-process research and development
IRS
U.S. Internal Revenue Service
IV
intravenous
Janssen
Janssen Biotech Inc.
J&J
Johnson & Johnson
King
King Pharmaceuticals LLC (formerly King Pharmaceuticals, Inc.)
LDL
low density lipoprotein
LEP
Legacy Established Products
LIBOR
London Interbank Offered Rate
Lilly
Eli Lilly & Company
LOE
loss of exclusivity
MCC
Merkel cell carcinoma
MCO
managed care organization
MD&A
Management s Discussion and Analysis of Financial Condition and Results of Operations
Medivation
Medivation LLC (formerly Medivation, Inc.)
Merck
Merck & Co., Inc.
Meridian
Meridian Medical Technologies, Inc.
Moody s
Moody s Investors Service
NDA
new drug application
NSCLC
non-small cell lung cancer
NYSE
New York Stock Exchange
OPKO
OPKO Health, Inc.
OTC
over-the-counter
PARP
poly ADP ribose polymerase
PBM
pharmacy benefit manager
Pharmacia
Pharmacia Corporation
PP&E
property, plant & equipment
PsA
psoriatic arthritis
Quarterly Report on Form 10-Q
Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2019
RA
rheumatoid arthritis
RCC
renal cell carcinoma
R&D
research and development
ROU
right of use
Sandoz
Sandoz, Inc., a division of Novartis AG
SBS
short bowel syndrome
SEC
U.S. Securities and Exchange Commission
SFJ
SFJ Pharmaceuticals Group
Shire
Shire International GmbH
SI&A
selling, informational and administrative
SIP
sterile injectable pharmaceuticals
S&P
Standard and Poor s
Tax Cuts and Jobs Act or TCJA
legislation commonly referred to as the U.S. Tax Cuts and Jobs Act of 2017
Therachon
Therachon Holding AG
UC
ulcerative colitis
U.K.
United Kingdom
U.S.
United States
ViiV
ViiV Healthcare Limited
WRDM
Worldwide Research, Development and Medical
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
Three Months Ended
(MILLIONS, EXCEPT PER COMMON SHARE DATA)
March 31,
2019
April 1,
2018
Revenues
13,118
12,906
Costs and expenses:
Cost of sales(a)
2,433
2,563
Selling, informational and administrative expenses(a)
3,339
3,412
Research and development expenses(a)
1,703
1,743
Amortization of intangible assets
1,183
1,196
Restructuring charges and certain acquisition-related costs
46
43
Other (income)/deductions net
92
(178
Income from continuing operations before provision for taxes on income
4,323
4,127
Provision for taxes on income
433
556
Income from continuing operations
3,889
3,571
Discontinued operations net of tax
(1
Net income before allocation to noncontrolling interests
3,889
3,570
Less: Net income attributable to noncontrolling interests
Net income attributable to Pfizer Inc.
3,884
3,561
Earnings per common share basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders
0.69
0.60
Discontinued operations net of tax
Net income attributable to Pfizer Inc. common shareholders
0.69
0.60
Earnings per common share diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders
0.68
0.59
Discontinued operations net of tax
Net income attributable to Pfizer Inc. common shareholders
0.68
0.59
Weighted-average shares basic
5,635
5,957
Weighted-average shares diluted
5,750
6,057
(a)
Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(UNAUDITED)
Three Months Ended
(MILLIONS OF DOLLARS)
March 31,
2019
April 1,
2018
Net income before allocation to noncontrolling interests
3,889
3,570
Foreign currency translation adjustments, net
324
758
Reclassification adjustments
15
326
773
Unrealized holding gains/(losses) on derivative financial instruments, net
267
(114
Reclassification adjustments for (gains)/losses included in net income(a)
(263
44
(69
Unrealized holding gains on available-for-sale securities, net
40
160
Reclassification adjustments for (gains)/losses included in net income(a)
11
(174
Reclassification adjustments for unrealized gains included in Retained earnings(b)
(462
51
(476
Benefit plans: actuarial gains, net
163
Reclassification adjustments related to amortization
60
62
Reclassification adjustments related to settlements, net
37
Other
(23
(86
37
175
Reclassification adjustments related to amortization of prior service costs and other, net
(46
(46
Reclassification adjustments related to curtailments of prior service costs and other, net
(7
Other
(46
(51
Other comprehensive income, before tax
372
352
Tax provision on other comprehensive income
25
432
Other comprehensive income/(loss) before allocation to noncontrolling interests
348
(80
Comprehensive income before allocation to noncontrolling interests
4,237
3,490
Less: Comprehensive income attributable to noncontrolling interests
10
Comprehensive income attributable to Pfizer Inc.
4,236
3,480
(a)
Reclassified into Other (income)/deductions net and Cost of sales in the condensed consolidated statements of income. For additional information on amounts reclassified into Cost of sales, see Note 7E. Financial Instruments: Derivative Financial Instruments and Hedging Activities.
(b)
For additional information, see Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 in our 2018 Financial Report.
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(MILLIONS OF DOLLARS)
March 31,
2019
December 31,
2018
(Unaudited)
Assets
Cash and cash equivalents
1,937
1,139
Short-term investments
9,682
17,694
Trade accounts receivable, less allowance for doubtful accounts: 2019 $538; 2018 $541
9,599
8,025
Inventories
8,029
7,508
Current tax assets
3,598
3,374
Other current assets
2,567
2,461
Assets held for sale
9,877
9,725
Total current assets
45,290
49,926
Long-term investments
2,859
2,767
Property, plant and equipment, less accumulated depreciation: 2019 $16,158; 2018 $16,591
13,467
13,385
Identifiable intangible assets, less accumulated amortization
34,039
35,211
Goodwill
53,487
53,411
Noncurrent deferred tax assets and other noncurrent tax assets
1,946
1,924
Other noncurrent assets
4,333
2,799
Total assets
155,421
159,422
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt: 2019 $4,471; 2018 $4,776
9,410
8,831
Trade accounts payable
4,156
4,674
Dividends payable
2,047
Income taxes payable
1,849
1,265
Accrued compensation and related items
1,797
2,397
Other current liabilities
10,276
10,753
Liabilities held for sale
1,935
1,890
Total current liabilities
29,423
31,858
Long-term debt
35,733
32,909
Pension benefit obligations, net
5,125
5,272
Postretirement benefit obligations, net
1,332
1,338
Noncurrent deferred tax liabilities
3,591
3,700
Other taxes payable
14,712
14,737
Other noncurrent liabilities
6,346
5,850
Total liabilities
96,263
95,664
Commitments and Contingencies
Preferred stock
19
19
Common stock
468
467
Additional paid-in capital
86,635
86,253
Treasury stock
(110,781
(101,610
Retained earnings
93,388
89,554
Accumulated other comprehensive loss
(10,923
(11,275
Total Pfizer Inc. shareholders equity
58,806
63,407
Equity attributable to noncontrolling interests
352
351
Total equity
59,158
63,758
Total liabilities and equity
155,421
159,422
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY
PFIZER INC. SHAREHOLDERS
Preferred Stock
Common Stock
Treasury Stock
(MILLIONS, EXCEPT PREFERRED SHARES)
Shares
Stated Value
Shares
Par Value
Add l
Paid-In Capital
Shares
Cost
Retained Earnings
Accum. Other Comp.
Loss
Share-
holders Equity
Non-controlling interests
Total Equity
Balance, January 1, 2019
478
19
9,332
467
86,253
(3,615
(101,610
89,554
(11,275
63,407
351
63,758
Net income
3,884
3,884
3,889
Other comprehensive income/(loss), net of tax
353
353
(4
348
Cash dividends declared:
Common stock
(68
(68
(68
Preferred stock
Noncontrolling interests
Share-based payment transactions
26
383
(7
(306
78
78
Purchases of common stock
(180
(8,865
(8,865
(8,865
Preferred stock conversions and redemptions
(12
(1
(1
(1
Other(a)
19
19
19
Balance, March 31, 2019
466
19
9,358
468
86,635
(3,801
(110,781
93,388
(10,923
58,806
352
59,158
PFIZER INC. SHAREHOLDERS
Preferred Stock
Common Stock
Treasury Stock
(MILLIONS, EXCEPT PREFERRED SHARES)
Shares
Stated Value
Shares
Par Value
Add l
Paid-In Capital
Shares
Cost
Retained Earnings
Accum. Other Comp.
Loss
Share-
holders Equity
Non-controlling interests
Total Equity
Balance, January 1, 2018
524
21
9,275
464
84,278
(3,296
(89,425
85,291
(9,321
71,308
348
71,656
Net income
3,561
3,561
3,570
Other comprehensive income/(loss), net of tax
(81
(81
(80
Cash dividends declared:
Common stock
(65
(65
(65
Preferred stock
Noncontrolling interests
Share-based payment transactions
24
321
29
351
351
Purchases of common stock
(145
(6,063
(6,063
(6,063
Preferred stock conversions and redemptions
(11
(1
(1
(1
Other(b)
1,175
1,175
1,175
Balance, April 1, 2018
513
21
9,299
465
84,599
(3,437
(95,460
89,961
(9,402
70,184
358
70,541
(a)
Represents the cumulative effect of the adoption of a new accounting standard in the first quarter of 2019 for leases. For additional information, see Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards.
(b)
Represents the cumulative effect of the adoption of new accounting standards in the first quarter of 2018 for revenues, financial assets and liabilities, income tax accounting, and the reclassification of certain tax effects from Accumulated other comprehensive income. For additional information, see Notes to Consolidated Financial Statements Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 in Pfizer s 2018 Financial Report.
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
Three Months Ended
(MILLIONS OF DOLLARS)
March 31,
2019
April 1,
2018
Operating Activities
Net income before allocation to noncontrolling interests
3,889
3,570
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:
Depreciation and amortization
1,545
1,567
Asset write-offs and impairments
155
TCJA impact(a)
(131
(68
Deferred taxes from continuing operations
(60
294
Share-based compensation expense
185
182
Benefit plan contributions in excess of expense
(151
(692
Other adjustments, net
(236
(161
Other changes in assets and liabilities, net of acquisitions and divestitures
(3,498
(2,715
Net cash provided by operating activities
1,698
1,983
Investing Activities
Purchases of property, plant and equipment
(460
(386
Purchases of short-term investments
(1,402
(913
Proceeds from redemptions/sales of short-term investments
3,601
6,463
Net proceeds from redemptions/sales of short-term investments with original maturities of three months or less